PROSTATE CANCER DETECTION BY DNA FINGERPRINTING

功能失调的基因和调节基因的异常表达， 推测是人类肿瘤发生的关键事件。 在前列腺癌中， 与许多其他类型的癌症不同， 检测到 通常，遗传改变包括缺失和 发现某些染色体区域的扩增。其他未定义的 癌基因和肿瘤抑制基因也可能在前列腺增生中起作用。 癌症发展 我们建议检测体细胞遗传变异， 前列腺癌和前列腺转移癌的检测方法。 基于DNA指纹识别。 在该程序中，使用具有 任意确定的序列被用来产生DNA的“指纹 来自同一供体的正常和前列腺肿瘤以及转移瘤。 以来 DNA序列在前列腺癌中经常丢失和/或扩增， 前列腺肿瘤和转移瘤的指纹应该具有不同的 当与相应正常人的指纹比较时， 同一个人的组织。 体细胞遗传改变，如 杂合性丢失和染色体获得，两个改变 经常参与癌细胞非整倍体的发展，可以 被这种非常强大的技术检测到。 这一建议集 参与恶性肿瘤的基因的II期鉴定的基础 前列腺癌的进展和转移。 建议的商业应用：该研究项目具有潜力， 开发肿瘤和/或转移分子标记物， 和专利。新发现的标记物可能被用作 前列腺癌易感性的诊断探针， 诊断前列腺癌，或作为前列腺转移的标志物 癌

Dysfunctional genes and aberrant expression of regulatory genes are speculated to be key events in human tumorigenesis. In prostate cancer, unlike many other types of cancer, few consistent genetic alterations are detected. Frequently, genetic alterations including deletions and amplifications of certain chromosomal regions are found. Other undefined oncogenes and tumor suppressor genes may also play a role in prostate cancer development. We propose to detect somatic genetic alterations in prostate cancer and prostate metastases through the technique of PCR- based DNA fingerprinting. In this procedure, a single primer with an arbitrarily determined sequence is used to produce "fingerprint" of DNAs from normal and prostate tumor and metastases from the same donor. Since DNA sequences are often lost and/or amplified in prostate cancer, the fingerprints of prostate tumors and metastases should have different band(s) when compared to the fingerprints of the corresponding normal tissue of the same individual. Somatic genetic alterations such as losses of heterozygosity and chromosomal gains, two alterations frequently involved in the development of aneuploidy of cancer cells, can be detected by this very powerful technique. This proposal sets groundwork for Phase II identification of gene(s) involved in malignant progression and metastasis of prostate cancer. PROPOSED COMMERCIAL APPLICATION: This research project has potential for developing tumor and/or metastasis molecular markers that would be unique and proprietary. The newly identified markers could possibly be used as diagnostic probes for the predisposition to prostate cancer, for early diagnosis of prostate cancer, or as a marker of metastasis of prostate cancer.